Review of 46 human studies links prenatal acetaminophen to higher ADHD/ASD risk; evidence is heterogeneous; cohort effect sizes are generally modest but larger in some biomarker studies; authors advise cautious, short‑term use under medical guidance.
Without a defined standard of care for tapering GLP-1 medications, physicians must navigate patient management amid insurer restrictions and high discontinuation rates